Key Points {#FPar1}
==========

LOOP is the first study to assess the impact of clinical specialty setting and geographic region of the USA on the diagnosis and management of patients with psoriatic arthritis (PsA).The median time from symptom onset to diagnosis of PsA was significantly shorter for patients enrolled by rheumatologists than for those enrolled by dermatologists.Patients enrolled from western regions of the USA tended to have less severe disease than those from eastern and central regions.

Introduction {#Sec1}
============

Psoriatic arthritis (PsA) is a primarily peripheral inflammatory joint disease that occurs in up to 30% of patients with psoriasis and can result in functional disability and reduced quality of life \[[@CR1]--[@CR3]\]. The historical Moll and Wright classification criteria identified five clinical subtypes of joint involvement in PsA: oligoarticular, polyarticular, distal, arthritis mutilans, and axial \[[@CR2], [@CR4], [@CR5]\]. Patients can also present with a variety of other clinical manifestations, including enthesitis, dactylitis, and nail dystrophy as well as comorbidities such as uveitis, inflammatory bowel disease, metabolic syndrome (obesity, hypertension, and hyperlipidemia), diabetes mellitus, and osteoporosis \[[@CR4], [@CR6]\]. The type and pattern of musculoskeletal involvement, clinical characteristics, and comorbidities can vary widely between patients or within the same patient over time. The heterogeneity of PsA therefore presents a diagnostic challenge, and patients may present to and be primarily managed by different clinical specialties, including rheumatology and dermatology \[[@CR2]\].

Early diagnosis and treatment of PsA is essential to prevent long-term structural joint damage and functional disability \[[@CR7]--[@CR9]\]. The American College of Rheumatology/National Psoriasis Foundation, the European League Against Rheumatism (EULAR), and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) recommend treatment with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), such as methotrexate or sulfasalazine, and/or biologic agents (bDMARDs) such as tumor necrosis factor inhibitors or interleukin-12/23 inhibitors \[[@CR10]--[@CR12]\]. Although evidence is lacking for the ability of csDMARDs to inhibit structural damage in PsA \[[@CR11], [@CR13]--[@CR17]\], effective inhibition has been demonstrated by bDMARDs \[[@CR11], [@CR14], [@CR18], [@CR19]\]. EULAR and GRAPPA also recommend a multidisciplinary approach to the treatment of PsA, with multispecialty assessment and management \[[@CR10], [@CR11]\].

Information on the factors that influence treatment management decisions for PsA is limited. The objective of this analysis was to investigate the impact of disease characteristics, clinical specialty setting, and geographic region on the diagnosis and management of patients with PsA. Disease activity and disease burden were also investigated across clinical specialty setting and geographic region.

Materials and Methods {#Sec2}
=====================

Study Design and Patients {#Sec3}
-------------------------

LOOP was a multicenter, cross-sectional, observational study conducted across 44 sites in the USA. Patients were aged ≥ 18 years with a suspected or established diagnosis of PsA and were routinely visiting a rheumatologist or a dermatologist (Fig. 1 in the Electronic Supplementary Material \[ESM\]). All patients enrolled in the study were assessed by both a rheumatologist and a dermatologist, and patients with a diagnosis of PsA confirmed by the rheumatologist were included in the present analysis.Fig. 1Distribution of time from symptom onset to psoriatic arthritis diagnosis. Percentages are calculated on non-missing values. Full analysis set

Assessments {#Sec4}
-----------

The primary outcomes were the time from inflammatory musculoskeletal symptom onset to PsA diagnosis; time from PsA diagnosis to first csDMARD; time from PsA diagnosis to first bDMARD; and time from first csDMARD to first bDMARD. Secondary outcomes included the current disease activity and disease burden as measured by clinical assessments (tender joint count in 68 joints, swollen joint count in 66 joints, Leeds Enthesitis Index \[LEI\], dactylitis count, Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\], psoriasis body surface area \[BSA\], psoriatic nail count, and Psoriasis Area and Severity Index \[PASI\]) and patient-reported outcomes (Health Assessment Questionnaire-Disability Index \[HAQ-DI\], Short Form 12-item health survey version 2.0 \[SF12v2\], Dermatology Life Quality Index \[DLQI\], and Patient Global Assessment of disease \[PtGA\]).

Statistical Analysis {#Sec5}
--------------------

Demographics of the study population are presented by enrolling specialty and geographic region (eastern, western, or central USA; see the ESM for further details) using descriptive statistics. The impact of clinical specialty setting and geographic region on time from symptom onset to PsA diagnosis was assessed using Kaplan--Meier analysis and a Cox proportional hazards model, with time as the response variable and clinical specialty or geographic region as the independent variable. Disease activity and disease burden were compared between clinical specialty using a two-sample *t* test and across geographic region using one-way analysis of variance.

Results {#Sec6}
=======

Patients and Demographics {#Sec7}
-------------------------

A total of 681 patients were enrolled in the LOOP study, 513 of whom had a diagnosis of PsA confirmed by a rheumatologist and were included in this analysis. Of these, 404 patients had their PsA diagnosis established prior to study entry (established PsA), whereas 109 patients had their PsA diagnosis confirmed during the study (suspected PsA). The majority of patients (57.3%) were female, with a mean age of 55.1 years and a mean body mass index of 31.5 (Table [1](#Tab1){ref-type="table"}). Over twice as many patients were recruited by rheumatologists (71.3%) than by dermatologists (28.7%). More patients were recruited from the eastern regions of the USA (67.8%) than central (18.3%) and western (13.8%) regions, which was proportional to the number of study sites in each region (see the ESM). Demographics were similar across clinical specialty setting and geographic region (Table [1](#Tab1){ref-type="table"}).Table 1Demographics and disease characteristics of patients categorized by the specialty of the enrolling physician and geographic region of the USACharacteristicSpecialty settingGeographic regionOverall (*n* = 513)Rheumatology (*n* = 366)Dermatology (*n* = 147)Eastern (*n* = 348)Central (*n *= 94)Western (*n* = 71)Age, years55.9 ± 13.553.1 ± 11.856.3 ± 12.753.7 ± 12.651.0 ± 14.655.1 ± 13.1Sex, male^a^151 (41.3)68 (46.3)134 (38.5)44 (46.8)41 (57.7)219 (42.7)Race^b^ White339 (92.6)128 (87.1)324 (93.1)85 (90.4)58 (81.7)467 (91.0) Black14 (3.8)11 (7.5)17 (4.9)7 (7.4)1 (1.4)25 (4.9) Asian6 (1.6)7 (4.8)3 (0.9)2 (2.1)8 (11.3)13 (2.5) Other3 (0.8)1 (0.7)4 (1.1)004 (0.8) Multiple4 (1.1)0004 (5.6)4 (0.8)Weight, kg89.2 ± 21.590.0 ± 20.1^b^89.1 ± 20.693.4 ± 20.985.4 ± 23.5^b^89.4 ± 21.1^b^BMI31.4 ± 7.331.8 ± 6.7^b^31.9 ± 7.032.2 ± 7.328.8 ± 7.3^b^31.5 ± 7.2^b^Data are presented as mean ± standard deviation or *N* (%) unless otherwise indicated*BMI* body mass index^a^Percentages calculated on non-missing values^b^Data missing for one patient

Treatment Patterns in the Overall Population {#Sec8}
--------------------------------------------

In the overall population, the median time from symptom onset to diagnosis of PsA was 1.2 years, with almost one-third of patients (31.8%) waiting \> 4 years for a diagnosis (Fig. [1](#Fig1){ref-type="fig"}). The median time from PsA diagnosis to first csDMARD and bDMARD was 1.0 and 2.4 years, respectively. In total, 282 (55.0%) and 354 (69.0%) patients received csDMARDs and bDMARDs, respectively. Prior to receiving a diagnosis of PsA, similar proportions of patients received therapy with csDMARDs (20.7%) and bDMARDs (23.6%). After diagnosis, the number of patients receiving these treatments increased, and a higher proportion of patients received therapy with bDMARDs (45.4%) versus csDMARDs (34.3%). A total of 73 (14.2%) patients did not receive treatment with csDMARDs or bDMARDs (although this included newly diagnosed patients who may not have started treatment, and in some cases these data may have been missing from patient records).

The majority of patients with a confirmed diagnosis of PsA presented with skin symptoms first (63.0%), with smaller proportions presenting with simultaneous skin and joint symptoms (21.1%) or joint symptoms first (14.2%). Patients who presented with joint symptoms first experienced a longer median time to PsA diagnosis (3.32 years) than those presenting with skin symptoms first (0.76 years) or simultaneous joint and skin symptoms (0.38 years).

Effect of Clinical Specialty Setting on the Management of PsA {#Sec9}
-------------------------------------------------------------

Patients enrolled by rheumatologists had a significantly shorter median time from symptom onset to diagnosis of PsA than those enrolled by dermatologists (1.0 vs. 2.6 years; hazard ratio 1.47; 95% confidence interval 1.20--1.78; *p* \< 0.001; Fig. [2](#Fig2){ref-type="fig"}). Numerical differences were seen between enrolling specialties in time to first csDMARD, time to first bDMARD, and time from csDMARD to bDMARD. However, these results should be interpreted with caution as data were not available for all patients.Fig. 2Timing of disease management steps by clinical specialty setting. \**p* value calculated using a Cox proportional hazards model, with time as a response variable and specialty as an independent variable. *p* values are not shown for the other three parameters because some data were missing. Error bars are 95% confidence intervals for symptom onset to psoriatic arthritis diagnosis and interquartile range for the remaining parameters. ^a^Estimated from Kaplan--Meier analyses. ^b^Full analysis set. ^c^Established patients only. *bDMARD* biologic disease-modifying antirheumatic drug, *csDMARD* conventional synthetic disease-modifying antirheumatic drug, *PsA* psoriatic arthritis

Disease activity and disease burden were generally similar for patients enrolled by rheumatologists and dermatologists (Table [2](#Tab2){ref-type="table"}). However, patients enrolled by dermatologists had significantly higher skin scores (as assessed by BSA and PASI), significantly higher enthesitis scores (as measured by LEI), and significantly worse quality of life (as measured by DLQI) than those enrolled by rheumatologists. In addition, patients enrolled by rheumatologists presented with a more severe average PtGA score at the time of diagnosis than those enrolled by dermatologists (Table [2](#Tab2){ref-type="table"}).Table 2Current disease activity and disease burden by clinical specialty settingMeasureRheumatologist (*n* = 366)Dermatologist (*n* = 147)*p* value^a^TJC688.2 ± 10.89.9 ± 10.30.095SJC663.4 ± 6.44.3 ± 6.00.154Enthesitis based on LEI1.0 ± 1.61.5 ± 1.8**0**.**005**Dactylitis count0.6 ± 1.50.8 ± 1.70.241BASDAI4.6 ± 3.2^b^4.3 ± 3.3^c^0.248BSA (%)5.0 ± 10.98.1 ± 14.5**0.024**Psoriatic nail count1.9 ± 3.1^d^2.0 ± 3.10.734PASI3.0 ± 5.1^e^5.5 ± 7.9^f^**\< 0.001**PtGA at the time of diagnosis6.7 ± 2.7^g^5.9 ± 3.1^h^**0.003**PtGA during last visit4.7 ± 2.9^i^4.7 ± 3.0^j^0.976HAQ-DI0.9 ± 0.70.7 ± 0.70.057SF12v2 PCS40.6 ± 10.5^g^41.8 ± 10.30.244SF12v2 MCS46.9 ± 11.1^g^47.9 ± 11.90.361DLQI5.4 ± 5.9^b^7.8 ± 7.4**\< 0.001**Bold text indicates significant differencesData are presented as mean ± standard deviation unless otherwise indicated*BASDAI* Bath Ankylosing Spondylitis Disease Activity Index, *BSA* body surface area with psoriasis, *DLQI* Dermatology Life Quality Index, *HAQ*-*DI* Health Assessment Questionnaire-Disability Index, *LEI* Leeds Enthesitis Index, *MCS* Mental Component Score, *PASI* Psoriasis Area and Severity Index, *PCS* Physical Component Score, *PtGA* Patient Global Assessment of disease, *SF12v2* Short Form 12-item health survey version 2.0, *SJC66* swollen joint count in 66 joints, *TJC68* tender joint count in 68 joints^a^*p* value from two-sample *t* test: rheumatologist vs. dermatologist^b^*n* = 361^c^*n* = 144^d^*n* = 321^e^*n* = 314^f^*n* = 145^g^*n* = 365^h^*n* = 138^i^*n* = 341^j^*n* = 65

Effect of Geographic Region on the Management of PsA {#Sec10}
----------------------------------------------------

Numerical differences were observed in the time from symptom onset to PsA diagnosis and time from PsA diagnosis to first csDMARD and bDMARD between geographic regions, but these were not significant. Patients enrolled in eastern and western regions of the USA experienced similar median times from symptom onset to PsA diagnosis (1.0 and 1.1 years, respectively) and from PsA diagnosis to first csDMARD (2.8 and 3.3 years, respectively). In comparison, patients enrolled in central regions had a numerically longer median time from symptom onset to PsA diagnosis (1.8 years) and a shorter time from PsA diagnosis to first csDMARD and bDMARD (1.6 and 1.9 years, respectively). The time from PsA diagnosis to first bDMARD was slightly longer for patients enrolled from eastern regions (3.1 years) than for those from western and central regions (2.1 and 1.9 years, respectively).

Patients enrolled from western regions tended to have less severe disease than those from eastern and central regions (Table [3](#Tab3){ref-type="table"}). This was observed in measures of joint involvement such as tender joint count and swollen joint count, as well as enthesitis score (LEI), dactylitis count, and BASDAI. This translated to improved quality-of-life scores in western patients as assessed by PtGA (at both time of diagnosis and last visit) as well as physical function measured by HAQ-DI and the SF12v2 Physical Component Score. However, measures of skin involvement were similar between the regional groups, as was DLQI.Table 3Current disease activity and disease burden by geographic regionMeasureEastern (*n* = 348)Central (*n* = 94)Western (*n* = 71)*p* value^a^TJC688.8 ± 10.710.6 ± 12.35.7 ± 7.4**0.012**SJC664.0 ± 5.74.6 ± 9.21.2 ± 2.1**0.001**Enthesitis based on LEI1.3 ± 1.70.9 ± 1.60.4 ± 1.1**\< 0.001**Dactylitis count0.7 ± 1.60.9 ± 1.70.3 ± 0.7**0.039**BASDAI4.9 ± 3.24.8 ± 3.2^b^2.7 ± 2.8**\< 0.001**BSA (%)6.3 ± 12.66.1 ± 13.83.6 ± 5.30.230Psoriatic nail count1.9 ± 3.2^c^1.5 ± 2.6^d^2.6 ± 3.1^e^0.103PASI3.8 ± 6.6^f^4.0 ± 6.3^g^3.5 ± 3.6^h^0.884PtGA at the time of diagnosis6.8 ± 2.8^i^6.0 ± 2.9^j^5.6 ± 2.9**\< 0.001**PtGA during last visit4.8 ± 2.9^k^5.4 ± 3.1^l^3.5 ± 2.8^m^**0.001**HAQ-DI0.9 ± 0.70.8 ± 0.70.4 ± 0.5**\< 0.001**SF12v2 PCS39.9 ± 9.8^n^40.4 ± 11.346.5 ± 10.9**\< 0.001**SF12v2 MCS47.1 ± 11.5^n^47.1 ± 10.648.0 ± 11.70.829DLQI6.0 ± 6.5^n^6.6 ± 6.3^o^6.1 ± 6.00.753Bold text indicates significant differencesData are presented as mean ± standard deviation unless otherwise indicated*BASDAI* Bath Ankylosing Spondylitis Disease Activity Index, *BSA* body surface area with psoriasis, *DLQI* Dermatology Life Quality Index, *HAQ*-*DI* Health Assessment Questionnaire-Disability Index, *LEI* Leeds Enthesitis Index, *MCS* Mental Component Score, *PASI* Psoriasis Area and Severity Index, *PCS* Physical Component Score, *PtGA* Patient Global Assessment of disease, *SF12v2* Short Form 12-item health survey version 2.0, *SJC66* swollen joint count in 66 joints, *TJC68* tender joint count in 68 joints^a^*p* value from one-way analysis of variance^b^*n* = 86^c^*n* = 312^d^*n* = 87^e^*n* = 69^f^*n* = 306^g^*n* = 85^h^*n* = 68^i^*n* = 345^j^*n* = 87^k^*n* = 298^l^*n* = 57^m^*n *= 51^n^*n* = 347^o^*n* = 90

Discussion {#Sec11}
==========

LOOP is the first study to assess the impact of clinical specialty setting and geographic region of the USA on the diagnosis and management of patients with PsA. Our results showed that specialty setting and geographic region were both associated with differences in the timing and choice of disease management steps, as well as disease activity and burden, in patients with PsA.

A key finding of this study was that, irrespective of clinical setting, there was a delay in the time from onset of PsA symptoms to diagnosis. The median time from onset of symptoms to diagnosis was 1.2 years, and a significant proportion of patients (approximately one-third) experienced delays of \> 4 years. The delay in diagnosis could impact long-term clinical and patient-reported outcomes; delays as short as ≥ 6 months have been shown to contribute to structural joint damage and poor physical function \[[@CR7]\], and similar results have been observed for delays of ≥ 1 and ≥ 2 years \[[@CR8], [@CR9]\]. Of note, the time from symptom onset to diagnosis was significantly longer for patients enrolled by dermatologists than for those enrolled by rheumatologists (2.6 vs. 1.0 years). This may be because rheumatologists are more familiar with the joint-related symptoms associated with PsA, which have some similarities with those observed in other forms of arthritis such as rheumatoid arthritis \[[@CR20]\]. Patients who presented with skin and joint symptoms simultaneously were more quickly diagnosed than those first presenting with either symptom type alone, probably because multifaceted symptoms and signs aided diagnosis.

Another important finding of the study was the variation in disease activity and disease burden across enrolling specialties and geographic regions. Patients enrolled in the dermatology setting had higher scores on measures of skin involvement and enthesitis than did those from the rheumatology setting, possibly because patients displaying more severe skin symptoms were more likely to be referred to a dermatologist. In addition, patients in western areas of the USA displayed less severe disease than those in central or eastern areas. The reasons for this are unclear and warrant further investigation. However, possible reasons could include differences in formulary restrictions and insurance policies and the availability of rheumatologists and/or dermatologists across the different regions. These factors may also have influenced the time to receiving treatment with csDMARDs and bDMARDs, although these parameters did not show significant differences across regions.

A multidisciplinary approach has been recommended by both EULAR and GRAPPA to improve the diagnosis and management of PsA \[[@CR10], [@CR11]\]. Co-management by rheumatologists and dermatologists has been shown to improve disease activity and quality-of-life outcomes in these patients \[[@CR21], [@CR22]\]. Studies have shown that psoriasis usually precedes the development of PsA by several years and that the prevalence of undiagnosed PsA in patients with psoriasis is high in the dermatology setting \[[@CR23]--[@CR27]\]. Our findings that patients enrolled in the dermatology setting experience a longer delay to diagnosis than those enrolled in the rheumatology setting support the use of a multidisciplinary approach for the management of PsA.

The main limitation of this study was its observational nature. Also, the full analysis set was based on confirmation of PsA by the rheumatologist only, so the data collected may not be reflective of the real-world management of patients across the USA. Similarly, categorization and analysis of data by enrolling specialty may not have adequately captured the complexity of the patient journey, such as how long the patient had been seeing that specialist, when and whether patients had prior care, and who made the initial diagnosis in patients with established PsA. In addition, conclusions are limited for some of the investigated parameters, as missing data restricted sample sizes and prevented statistical comparisons.

In summary, our results show that clinical specialty setting and geographic region can affect the timing and choice of disease management steps as well as disease activity and disease burden in patients with PsA in the USA. There was a substantial delay in the time from symptom onset to diagnosis, and this was significantly longer for patients enrolled by dermatologists than for those enrolled by rheumatologists. Clinical specialty setting also affected the severity of skin symptoms, and patients from eastern and central USA tended to have more severe disease than those from the western region. The delay in disease diagnosis and high disease activity in these patients highlights the need for a multidisciplinary approach in the diagnosis and management of PsA.
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